Our Products and Research & Development Pipeline

€213.1m - Total Revenue and Operating Income. Continued strong autonomous product. 21.3m doses - Quinvaxem®. Sales up from 6.3m doses in 2006 to 21.3m in 2007.
Products and R&D Pipeline Development stage
  Pre-clinic Phase 1 Phase 2 Phase 3 Marketed
Quinvaxem®          
Hepavax-Gene®          
MoRu-Viraten®          
Epaxal® Junior          
Epaxal®          
Vivotif®          
Dukoral®          
Inflexal® V          
Flavimum®          
Influenza seasonal          
H9N2*          
Rabies antibody cocktail          
Malaria          
Tuberculosis          
Ebola          
H7N1/Flupan*          
Factor VL/C          
HIV          
H5N1 Avian antibodies*          

* pandemic influenza

Back to top ↑